145 related articles for article (PubMed ID: 22377620)
1. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
Alinari L; Baiocchi RA; Praetorius-Ibba M
Autophagy; 2012 Mar; 8(3):416-7. PubMed ID: 22377620
[TBL] [Abstract][Full Text] [Related]
2. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
[TBL] [Abstract][Full Text] [Related]
3. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
Liu Q; Alinari L; Chen CS; Yan F; Dalton JT; Lapalombella R; Zhang X; Mani R; Lin T; Byrd JC; Baiocchi RA; Muthusamy N
Clin Cancer Res; 2010 Jun; 16(12):3182-92. PubMed ID: 20460491
[TBL] [Abstract][Full Text] [Related]
4. FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells.
Zhang L; Wang H; Ding K; Xu J
Toxicol Lett; 2015 Jul; 236(1):43-59. PubMed ID: 25939952
[TBL] [Abstract][Full Text] [Related]
5. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Mani R; Chiang CL; Frissora FW; Yan R; Mo X; Baskar S; Rader C; Klisovic R; Phelps MA; Chen CS; Lee RJ; Byrd JC; Baiocchi R; Lee LJ; Muthusamy N
Exp Hematol; 2015 Sep; 43(9):770-4.e2. PubMed ID: 25937048
[TBL] [Abstract][Full Text] [Related]
6. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
7. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy.
Zhang N; Qi Y; Wadham C; Wang L; Warren A; Di W; Xia P
Autophagy; 2010 Nov; 6(8):1157-67. PubMed ID: 20935520
[TBL] [Abstract][Full Text] [Related]
8. Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Estrada-Bernal A; Palanichamy K; Ray Chaudhury A; Van Brocklyn JR
Neuro Oncol; 2012 Apr; 14(4):405-15. PubMed ID: 22351749
[TBL] [Abstract][Full Text] [Related]
9. FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells.
Wallington-Beddoe CT; Hewson J; Bradstock KF; Bendall LJ
Autophagy; 2011 Jul; 7(7):707-15. PubMed ID: 21460633
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of ROS in U266 cell death induced by FTY720].
Li YC; Liu ZG; Yao K; Wang HH; Hu R; Yang W; Liao AJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):643-6. PubMed ID: 23815914
[TBL] [Abstract][Full Text] [Related]
11. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy.
Zhang N; Dai L; Qi Y; Di W; Xia P
Int J Oncol; 2013 Jun; 42(6):2053-9. PubMed ID: 23592281
[TBL] [Abstract][Full Text] [Related]
12. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.
Nagaoka Y; Otsuki K; Fujita T; Uesato S
Biol Pharm Bull; 2008 Jun; 31(6):1177-81. PubMed ID: 18520051
[TBL] [Abstract][Full Text] [Related]
13. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.
Marvaso G; Barone A; Amodio N; Raimondi L; Agosti V; Altomare E; Scotti V; Lombardi A; Bianco R; Bianco C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2014 Jun; 15(6):797-805. PubMed ID: 24657936
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets of FTY720 (fingolimod).
Pitman MR; Woodcock JM; Lopez AF; Pitson SM
Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
[TBL] [Abstract][Full Text] [Related]
16. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
17. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
Wallington-Beddoe CT; Don AS; Hewson J; Qiao Q; Papa RA; Lock RB; Bradstock KF; Bendall LJ
PLoS One; 2012; 7(5):e36429. PubMed ID: 22570713
[TBL] [Abstract][Full Text] [Related]
18. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic approach to steroid-resistant dermatitis using novel immunomodulator FTY720 (Fingolimod) in combination with betamethasone ointment in NC/Nga mice.
Tsuji T; Yoshida Y; Iwatsuki R; Inoue M; Fujita T; Kohno T
Biol Pharm Bull; 2012; 35(8):1314-9. PubMed ID: 22863931
[TBL] [Abstract][Full Text] [Related]
20. Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model.
Moon MH; Jeong JK; Lee JH; Park YG; Lee YJ; Seol JW; Park SY
Exp Mol Med; 2012 Oct; 44(10):603-14. PubMed ID: 22859500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
